Article Information
History
- February 15, 2023.
Article Versions
- Version 1 (March 12, 2022 - 23:33).
- Version 2 (November 4, 2022 - 07:42).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Amy L. Kennalley, MSa,*,
- Jessica L. Fanelli, BSa,
- John A. Furst Jr., BSa,
- Nicholas J. Mynarski, BSa,
- Margaret A. Jarvis, MDb,
- Stephanie D. Nichols, PharmD, MPHc,
- Kenneth L. McCall, PharmDd and
- Brian J. Piper, PhDa,e
- aDepartment of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, 18510
- bGeisinger Clinic, Geisinger, Danville, PA, 17821
- cDepartment of Pharmacy Practice, University of New England, Portland, ME 04103
- dDepartment of Pharmacy Practice, Binghamton University, Johnson City, NY 13790
- eCenter for Pharmacy Innovation and Outcomes, Forty Fort, PA, 18704
- ↵*Corresponding Author:
Amy L. Kennalley, MS, 525 Pine St, Scranton, PA 18510, (925) 408-5226; amykennalley{at}gmail.com; akennalley{at}som.geisinger.edu
Posted February 15, 2023.
Reversal of increases in methadone distribution for opioid use disorder in the US during the COVID-19 pandemic
